Meeting Acute Migraine Treatment Needs through Novel Treatment Formulations

Neurotherapeutics

Volumn 7, Issue 2, 2010, Pages 153-158

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Dihydroergotamine; effervescent; inhalation treatment; iontophoresis; needle free; pain free; triptan

Indexed keywords

5 [[(3 PHENOXYBENZYL)(1,2,3,4 TETRAHYDRO 1 NAPHTHYL)AMINO]CARBONYL]TRIMELLITIC ACID; ADENOSINE TRIPHOSPHATE; BUTALBITAL; CALCITONIN GENE RELATED PEPTIDE; CAMBIA; DICLOFENAC; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE; ERGOTAMINE; OPIATE; PLACEBO; PURINERGIC P2X3 RECEPTOR; RIZATRIPTAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; EFFERVESCENT TABLET; HEALTH CARE DELIVERY; HEALTH CARE NEED; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NERVE STIMULATION; NOCICEPTION; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE; REACTION TIME; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TRIGEMINAL NERVE;

ANALGESICS, NON-NARCOTIC; DICLOFENAC; DIHYDROERGOTAMINE; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG PRESCRIPTIONS; HUMANS; MIGRAINE DISORDERS; SUMATRIPTAN;

EID: 77953261677     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.03.004     Document Type: Article

References (30)

1. Bigal M.E., Borucho S., Serrano D., and Lipton R.B. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 29 (2009) 891-897
2. Revicki D.A., Kimel M., Beusterien K., et al. Validation of the Revised Patient Perception of Migraine Questionnaire: measuring satisfaction with acute migraine treatment. Headache 46 (2006) 240-252
3. Davies G.M., Santanello N., and Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 20 (2000) 554-560
4. Diener H.C., and Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10 (2001) 1831-1845
5. Velati D., Viana M., Cresta S., et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol 580 (2008) 43-47
6. Lipton R.B., Hamelsky B.A., and Dayno J.M. What do patients with migraine want from acute migraine treatment?. Headache 42 suppl 1 (2002) S3-S9
7. Aurora S., Kori S., Barrodale P., Nelsen A., and McDonald S. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache 47 (2007) 1443-1446
8. Dodick D., and Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 46 suppl 4 (2006) S182-S191
9. Bartley J. Could glial activation be a factor in migraine?. Med Hypotheses 72 (2009) 255-257
10. Thalakoti S., Patil V.V., Damodaram S., et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47 (2007) 1008-1025
11. Damodaram S., Thalakoti S., Freeman S.E., Garrett F.G., and Durham P.L. Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49 (2009) 5-20
12. Schock S.C., Munyao N., Yakubchyk Y., et al. Cortical spreading depression releases ATP into the extracellular space and purinergic receptor activation contributes to the induction of ischemic tolerance. Brain Res 1168 (2007) 129-138
13. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., and Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8 (2002) 136-142
14. Moskowitz M.A. Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. Headache 48 (2008) 688-690
15. Bie B.H., Zhang Y.H., and Zhao Z.Q. Inhibition of P2X receptor-mediated inward current by protein kinase C in small-diameter dorsal root ganglion neurons of adult rats. Neurosci Bull 25 (2009) 179-186
16. Burnstock G. Purinergic receptors and pain. Curr Pharm Des 15 (2009) 1717-1735
17. Masterson C., and Durham P. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons involves activation of α2-adrenergic receptors. Cephalalgia (2010) in press
18. Sarchielli P., Pini L.A., Zanchin G., et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26 (2006) 257-265
19. Cady R.K., Vause C.V., Ho T.W., Bigal M.E., and Durham P.L. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 49 (2009) 1258-1266
20. th Annual Scientific Meeting of the American Headache Society; June 28, 2008; Boston.
21. Brandes J.L., Cady R.K., Freitag F.G., et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 49 (2009) 1435-1444
22. Terhaag B., Hoffmann A., Barkworth M., and Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther 38 (2000) 546-551
23. Diener H.C., Montagna P., Gács G., et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 26 (2005) 537-547
24. Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med 19 (2006) 47-53
25. Siekmeier R., and Scheuch G. Systemic treatment by inhalation of macromolecules - principles, problems, and examples. J Physiol Pharmacol 59 suppl 6 (2008) 53-79
26. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6 (2007) 67-74
27. Shrewsbury S.B., Cook R.O., Taylor G., Edwards C., and Ramadan N.M. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache 48 (2008) 355-367
28. Cook R.O., Shrewsbury S.B., and Ramadan N.M. Reduced adverse event profile of orally inhaled DHE (MAP00004) vs. IV DHE: potential mechanism. Headache 49 (2009) 1423-1434
29. Aurora S.K., Rozen T.D., Kori S.H., and Shrewsbury S.B. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49 (2009) 826-837
30. Silberstein S, Kori SH, Aurora S, et al. LEVADEX, a novel orally inhaled treatment for acute migraine: efficacy and tolerability results of a Phase 3 study. Presented at the 14th International Headache Congress; September 12, 2009; Philadelphia.